| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03257169 |
| P698 | PubMed publication ID | 14720029 |
| P2093 | author name string | David W A Milligan | |
| Sean B Ainsworth | |||
| P2860 | cites work | Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams | Q59317359 |
| Isolation and characterization of the human pulmonary surfactant apoprotein gene | Q24294842 | ||
| Doctors revise declaration of Helsinki | Q24524807 | ||
| Altered stability of pulmonary surfactant in SP-C-deficient mice | Q24626562 | ||
| Characterization of a second human pulmonary surfactant-associated protein SP-A gene | Q28186207 | ||
| A mutation in the surfactant protein C gene associated with familial interstitial lung disease | Q28201394 | ||
| Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia | Q28251863 | ||
| Structural comparison of recombinant pulmonary surfactant protein SP-A derived from two human coding sequences: implications for the chain composition of natural human SP-A | Q28262888 | ||
| Structure and properties of surfactant protein B | Q28288717 | ||
| High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome | Q30305906 | ||
| Functional roles and structural analysis of lung collectins SP-A and SP-D. | Q30642550 | ||
| Biophysical activity of an artificial surfactant containing an analogue of surfactant protein (SP)-C and native SP-B | Q31270991 | ||
| Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial) | Q33623794 | ||
| Isolation of an ovine pulmonary surfactant-associated anionic peptide bactericidal for Pasteurella haemolytica | Q33626881 | ||
| Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice | Q34008084 | ||
| Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group | Q34334293 | ||
| Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. | Q34340002 | ||
| Association between the surfactant protein A (SP-A) gene locus and respiratory-distress syndrome in the Finnish population | Q34390422 | ||
| The role of lipids in pulmonary surfactant. | Q34479899 | ||
| Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation | Q34490111 | ||
| Follow up of premature babies treated with artificial surfactant (ALEC). | Q35066317 | ||
| Cost implications of different approaches to the prevention of respiratory distress syndrome | Q35066402 | ||
| Artificial surfactant and natural surfactant. Comparative study of the effects on premature rabbit lungs | Q35114403 | ||
| Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial | Q35170840 | ||
| Systematic review of prophylactic vs rescue surfactant | Q35285796 | ||
| Haemodynamic effects of altering arterial oxygen saturation in preterm infants with respiratory failure | Q35288052 | ||
| Changing prognosis for babies of less than 28 weeks' gestation in the north of England between 1983 and 1994. Northern Neonatal Network | Q36242092 | ||
| Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome | Q36711589 | ||
| "Click test": rapid diagnosis of the respiratory distress syndrome | Q36740707 | ||
| Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome | Q36860005 | ||
| Cerebral blood flow velocity changes after rapid administration of surfactant | Q38365505 | ||
| Effects of artificial surfactant on lung function and blood gases in idiopathic respiratory distress syndrome | Q38937132 | ||
| Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface: II. Monolayers of pulmonary surfactant protein SP-C and phospholipids | Q39458242 | ||
| Rhabdomyolysis as a complication of 5-azacytidine | Q39490799 | ||
| Physical and physiological properties of dry lung surfactant | Q40363763 | ||
| Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome | Q40395476 | ||
| Surfactant and pulmonary blood flow distributions following treatment of premature lambs with natural surfactant | Q40925547 | ||
| Content of dipalmitoyl phosphatidylcholine in lung surfactant: ramifications for surface activity | Q40941153 | ||
| Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I. | Q41180671 | ||
| The composition and function of reptilian pulmonary surfactant | Q41198951 | ||
| The pulmonary surfactant system: biochemical and clinical aspects | Q41262570 | ||
| Molecular structures and interactions of pulmonary surfactant components | Q41434943 | ||
| Immediate effects on lung function of instilled human surfactant in mechanically ventilated newborn infants with IRDS. | Q41877807 | ||
| Nebulisation of surfactants in an animal model of neonatal respiratory distress | Q41923084 | ||
| Dose‐response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS) | Q41990088 | ||
| Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C. | Q41995834 | ||
| A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation | Q42072584 | ||
| Comparison of surface properties and physiological effects of a synthetic and a natural surfactant in preterm rabbits | Q42115146 | ||
| Secondary structure and biophysical activity of synthetic analogues of the pulmonary surfactant polypeptide SP-C | Q42160638 | ||
| Hydrophobic proteins of lamellated osmiophilic bodies isolated from pig lung | Q42169310 | ||
| The surface properties of chemically synthesized peptides analogous to human pulmonary surfactant protein SP-C. | Q42643672 | ||
| Comparison of rSP-C surfactant with natural and synthetic surfactants after late treatment in a rat model of the acute respiratory distress syndrome | Q43184317 | ||
| Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome | Q43480701 | ||
| Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease | Q43594810 | ||
| Outcome at 1-year adjusted age of 957 infants weighing more than 1250 grams with respiratory distress syndrome randomized to receive synthetic surfactant or air placebo. American and Canadian Exosurf Neonatal Study Groups | Q43801826 | ||
| Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation | Q43819975 | ||
| Component-specific surface and physiological activity in bovine-derived lung surfactants | Q43884033 | ||
| Declining severity adjusted mortality: evidence of improving neonatal intensive care | Q44242038 | ||
| Early versus late surfactant treatment in preterm infants of 27 to 32 weeks' gestational age: a multicenter controlled clinical trial | Q44317806 | ||
| Surfactant protein SP-B induces ordering at the surface of model membrane bilayers | Q44424907 | ||
| Surfactant Protein A, Phosphatidylcholine, and Surfactant Inhibitors in Epithelial Lining Fluid: Correlation with Surface Activity, Severity of Respiratory Distress Syndrome, and Outcome in Small Premature Infants | Q44590921 | ||
| One-year follow-up of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo. Canadian Exosurf Neonatal Study Group. Canadian Exosurf Neonatal Follow- | Q44654813 | ||
| A multicenter randomized, placebo-controlled trial of surfactant therapy for respiratory distress syndrome | Q45193275 | ||
| Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits | Q46041733 | ||
| Effect of volume and dose on the pulmonary distribution of exogenous surfactant administered to normal rabbits or to rabbits with oleic acid lung injury | Q46099988 | ||
| Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats | Q46112742 | ||
| Synthetic mimics of surfactant proteins B and C: in vitro surface activity and effects on lung compliance in two animal models of surfactant deficiency | Q46291785 | ||
| Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity | Q46372703 | ||
| An amphipathic alpha-helical decapeptide in phosphatidylcholine is an effective synthetic lung surfactant. | Q46686615 | ||
| Distribution of surfactant, lung compliance, and aeration of preterm rabbit lungs after surfactant therapy and conventional and high-frequency oscillatory ventilation | Q46758795 | ||
| A synthetic segment of surfactant protein A: structure, in vitro surface activity, and in vivo efficacy | Q46820486 | ||
| Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure | Q47202761 | ||
| Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association | Q47252098 | ||
| Trends in mortality and cerebral palsy in a geographically based cohort of very low birth weight neonates born between 1982 to 1994. | Q47291458 | ||
| Birth weight and age-specific analysis of the 1990 US infant mortality drop. Was it surfactant? | Q47315142 | ||
| Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant | Q47438728 | ||
| Synthetic peptide-containing surfactants--evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. | Q47733159 | ||
| Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs | Q48642200 | ||
| Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease | Q50113611 | ||
| Double-blind 1-year follow-up of 1540 infants with respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air in four clinical trials. American and Canadian Exosurf Neonatal Study Groups. | Q50519855 | ||
| Double-blind evaluation of developmental and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo. | Q50519856 | ||
| Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. | Q50949616 | ||
| Hydrophobic lung surfactant proteins B and C remain associated with surface film during dynamic cyclic area changes. | Q51475087 | ||
| Optimizing alveolar expansion prolongs the effectiveness of exogenous surfactant therapy in the adult rabbit. | Q51656273 | ||
| A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs | Q51691674 | ||
| Comparative randomized study: administration of natural and synthetic surfactant to premature newborns with respiratory distress syndrome. | Q51723906 | ||
| One-year outcome in 232 premature infants with birth weights of 750 to 1249 grams and respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air placebo. Canadian Exosurf Neonatal Study Group. | Q52016471 | ||
| One-year follow-up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo at birth: results of a double-blind trial. American Exosurf Neonatal Study Group I. | Q52016478 | ||
| One-year follow-up evaluation of 260 premature infants with respiratory distress syndrome and birth weights of 700 to 1350 grams randomized to two rescue doses of synthetic surfactant or air placebo. American Exosurf Neonatal Study Group I. | Q52208534 | ||
| Circulatory changes after surfactant bolus instillation in lung-lavaged adult rabbits. | Q53004187 | ||
| Rapid tracheal infusion of surfactant versus bolus instillation in rabbits: effects on oxygenation, blood pressure and surfactant distribution. | Q53009158 | ||
| [Early continuous positive pressure in the labor room] | Q53800661 | ||
| Surfactant protein-A deficiency in a primate model of bronchopulmonary dysplasia. | Q54611153 | ||
| An amphipathic helical motif common to tumourolytic polypeptide NK-lysin and pulmonary surfactant polypeptide SP-B. | Q54613985 | ||
| Artificial surfactant therapy in hyaline-membrane disease | Q55062244 | ||
| Cerebral blood flow and plasma hypoxanthine in relation to surfactant treatment | Q57198897 | ||
| Prospective Randomized Multicenter Comparison of High-Frequency Oscillatory Ventilation and Conventional Ventilation in Preterm Infants of Less Than 30 Weeks With Respiratory Distress Syndrome | Q57764197 | ||
| Acute Effects on Systemic and Pulmonary Hemodynamics of Intratracheal Instillation of Porcine Surfactant or Saline in Surfactant-Depleted Newborn Piglets | Q58143946 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 417-433 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Treatments in Respiratory Medicine | Q15755236 |
| P1476 | title | Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review | |
| P478 | volume | 1 |
| Q46844598 | Characterization of bovine surfactant proteins B and C by electrospray ionization mass spectrometry |
| Q34103139 | Cross-talk between pulmonary injury, oxidant stress, and gap junctional communication. |
| Q51707644 | DPP4 inhibitors increase differentially the expression of surfactant proteins in Fischer 344 rats. |
| Q34411762 | Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome |
| Q36090662 | Lucinactant: in neonatal respiratory distress syndrome |
| Q42691412 | Lung volume recruitment after surfactant administration modifies spatial distribution of ventilation. |
| Q46799280 | Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications. |
| Q36334819 | Pathophysiology of neonatal respiratory distress syndrome: implications for early treatment strategies |
| Q24243198 | Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome |
| Q24244224 | Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome |
| Q24240106 | Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome |
| Q24244576 | Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome |
| Q43560852 | Surfactant dysfunction mutations in children's interstitial lung disease and beyond |
| Q35159752 | Synthetic liposomes are protective from bleomycin-induced lung toxicity |
| Q37462109 | Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials |
Search more.